Detalhe da pesquisa
1.
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
Breast
; 64: 151-158, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35487845
2.
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
Eur J Cancer
; 152: 223-232, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34147014
3.
Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Br J Pharmacol
; 147(8): 905-16, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16474415